REMARKS

Claims 1 through 83 have been restricted as follows:

Claims 1 through 22 and 42, directed to a grafted antibody or functional fragment thereof, which has specific binding activity for a cryptic collagen epitope, wherein said antibody comprises one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 20, SEQ ID NO:22, and SEQ ID NO: 24, and wherein said antibody further comprises one or more CDRs selected from the group of CDRs consisting of SEQ ID NOs: 43-86 and 154-162 (HUIV26);

Claims 23 through 42, directed to a grafted antibody or functional fragment thereof, which has specific binding activity for a cryptic collagen epitope, wherein said antibody comprises one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs selected from the group consisting of SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 32, SEQ ID NO: 34, and SEQ ID NO: 36, and wherein said antibody further comprises one or more CDRs selected from the group of CDRs consisting of SEQ ID NOs: 87-153 and 358 (HUIV77);

Claim 43, directed to a nucleic acid molecule encoding HUIV26 antibody variants;

Claims 44 through 47, directed to a method for targeting angiogenic vasculature using HUIV26 antibody variants;

Claims 48 through 50, directed to a method for inhibiting angiogenesis using HUIV26 antibody variants;

Claims 51 through 54, directed to a method for targeting a tumor using HUIV26 antibody variants;

Claims 55 through 57, directed to a method for inhibiting tumor growth using HUIV26 antibody variants;

Claims 58 through 60, directed to a method for detecting angiogenic vasculature using HUIV26 antibody variants;

Claims 61 through 63, directed to a method for inhibiting metastasis using HUIV26 antibody variants;

Claims 64 through 67, directed to a method for targeting angiogenic vasculature using HUIV77 antibody variants;

Claims 68 through 70, directed to a method for inhibiting angiogenesis using HUIV77 antibody variants;

Claims 71 through 74, directed to a method for targeting a tumor using HUIV77 antibody variants;

Claims 75 through 77 and 81 through 83, directed to a method for inhibiting tumor growth using HUIV77 antibody variants; and

Claims 78 through 80, directed to a method for detecting angiogenic vasculature using HUIV77 antibody variants.

As understood by Applicant, the Restriction Requirement appears to indicate that each of separate sequences is a distinct invention rather than the groups outlined above being restricted groups of inventions. Applicant respectfully requests clarification if this understanding is incorrect.

The Examiner requests that one of the groups of claims be elected for examination. Although the restriction requirement is traversed for the reasons set forth below, Applicant elects the antibody having SEQ ID NOS:26, 28, 63, 20, 22 and 77 for examination. This antibody reads on claims 1-3.

The Restriction Requirement is traversed with respect to the division of the claims into what appears to be, as discussed above, separate inventions for each of the sequences. The Restriction Requirement indicates that the inventions of the groups of claims 1-22 and 42 and claims 23-42 and 43 are disclosed as biologically and chemically distinct, unrelated in structure and/or function and/or made by and/or used in different methods and are therefore distinct. Applicant points out that all of the antibodies of claims 1-22 are HUIV26 antibodies having structural similarity. These antibodies are variants having one or more amino acid substitution in the CDRs of antibody HUIV26. Furthermore, these antibodies have a functional similarity in that they have binding activity for a collagen epitope. Therefore, in contrast to the assertion in the Restriction Requirement, the individual sequences of claims 1-22 have related structure and function. Accordingly, it is respectfully submitted that these sequences should more properly be considered species rather than separate and distinct inventions subject to a restriction requirement. Accordingly, Applicants respectfully request reconsideration of the restriction requirement and consideration of examining the sequences as species.

Applicants elect the antibody having SEQ ID NOS:26, 28, 63, 20, 22 and 77 for examination and respectfully request that the antibody be considered a species and examined with other species. The Examiner is invited to call the undersigned agent if there are any questions.

Respectfully submitted,

Date: December 22, 2003



Deborah L. Cadena
Registration No. 44,048
Telephone: (858) 535-9001
Facsimile: (858) 535-8949

McDERMOTT, WILL & EMERY
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122